The pharmacy counter was a state decision
Federal regulators built the approval pathway for biosimilars, as described in the FDA’s biosimilar information, but states decided what pharmacists could do with those products once a prescription reached the pharmacy. Substitution is a matter of state pharmacy law, so each legislature had to answer a practical question: could a pharmacist dispense a biosimilar instead of the biologic named on the prescription, and if so, under what conditions?
Approval and substitution are different steps. Federal action established the pathway for evaluating which products could enter the market as biosimilars. State law governed what happened next: the transaction among the prescription, the pharmacist, the prescriber and the patient. A product could sit inside the federal biosimilar system without automatically replacing the product written on a prescription at every pharmacy.
By 2015, enough states had acted that tracking their differences had become its own project, including the state limits on biosimilar substitution. The laws did not all use the same process, even though many addressed the same basic concerns.
The common building blocks
Most state laws circled the same few choices. Substitution generally required the biosimilar to be designated interchangeable at the federal level. Without that designation, the state substitution process generally did not apply.
The prescriber also kept a way to prevent the switch. A prescriber who wanted the patient to receive the named product had a mechanism to insist on it. State rules preserved a role for the clinician who wrote the prescription, so the switch was never the pharmacist’s decision alone.
Recordkeeping requirements followed. Pharmacies had to track the product actually dispensed, so the record showed what the patient received. No one had to assume the originally named biologic had been supplied.
These provisions added up to a framework. Each state wrote its own version. The federal designation addressed whether a biosimilar could qualify for substitution. State law addressed how that substitution happened at the counter.
Notification became the main fault line
The friction was mostly about notification. Some states added a step: the prescriber had to be told which product the patient actually received. That made the substitution visible to the prescribing clinician after dispensing. Without that step, the clinician would be left to assume the product named on the prescription was the one supplied.
Manufacturers of originator biologics favored notification. Pharmacy and payer groups argued that it added paperwork without clinical benefit. States split on the timing of the notice, the method for sending it, and whether the requirement expired after a few years. Both sides accepted that substitution could happen. The dispute was over what had to occur afterward.
Each of those details changes how substitution works in practice. The timing determines whether the prescriber learns about the change quickly or later. The method affects how much work the pharmacy must do. An expiration provision means a requirement may not be permanent, even though substitution remains available. Two states can both allow substitution of a federally interchangeable biosimilar and still place different responsibilities on pharmacies and prescribers.
State rules leave different responsibilities at the counter
The state rule shapes whether a pharmacist may substitute, whether the prescriber learns about it, and what the records show about which product was dispensed. The rule does not operate in the abstract. It plays out one prescription at a time, at a specific pharmacy, with a specific product. Where a prescription is filled can therefore change what the patient receives and what the patient pays.
Access is divided between federal and state decisions. Federal regulators established the FDA drug regulation framework. State legislatures determined how a qualifying product could move from prescription to dispensing. No single substitution rule came out of that split. What emerged was a set of state systems built from similar parts and separated by important details.
The GLP-1 telehealth provider comparison covers provider options rather than the biosimilar substitution systems discussed here.
The policy result is a layered process. Federal regulators determine whether a product can qualify as an interchangeable biosimilar, while state law determines how the product may be substituted, documented and communicated once it reaches the pharmacy.